Technical Analysis for ONCO - Onconetix, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.12 | -3.24% | 0.00 |
ONCO closed down 3.24 percent on Friday, April 26, 2024, on 39 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Wide Bands | Range Expansion | -3.24% | |
| Oversold Stochastic | Weakness | -3.24% | |
| Lower Bollinger Band Walk | Weakness | -4.59% |
| Alert | Time |
|---|---|
| Down 5% | about 12 hours ago |
| Fell Below Previous Day's Low | about 12 hours ago |
| Possible NR7 | about 13 hours ago |
| Possible Inside Day | about 13 hours ago |
| 60 Minute Opening Range Breakdown | about 17 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/30/2024
Onconetix, Inc. (formerly Blue Water Biotech, Inc. (BWV)) is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The Company currently has Entadfi®, an FDA approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix®, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology FDA Disorders Prostate Cancer Urology Benign Prostatic Hyperplasia Bph Men's Health Prostate Treatment Of Benign Prostatic Hyperplasia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology FDA Disorders Prostate Cancer Urology Benign Prostatic Hyperplasia Bph Men's Health Prostate Treatment Of Benign Prostatic Hyperplasia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.58 |
| 52 Week Low | 0.1001 |
| Average Volume | 401,086 |
| 200-Day Moving Average | 0.41 |
| 50-Day Moving Average | 0.16 |
| 20-Day Moving Average | 0.14 |
| 10-Day Moving Average | 0.12 |
| Average True Range | 0.02 |
| RSI (14) | 29.58 |
| ADX | 21.73 |
| +DI | 25.71 |
| -DI | 21.99 |
| Chandelier Exit (Long, 3 ATRs) | 0.20 |
| Chandelier Exit (Short, 3 ATRs) | 0.15 |
| Upper Bollinger Bands | 0.18 |
| Lower Bollinger Band | 0.11 |
| Percent B (%b) | 0.16 |
| BandWidth | 51.45 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.01 |
| MACD Histogram | -0.0019 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.13 | ||||
| Resistance 3 (R3) | 0.13 | 0.12 | 0.13 | ||
| Resistance 2 (R2) | 0.12 | 0.12 | 0.12 | 0.12 | |
| Resistance 1 (R1) | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 |
| Pivot Point | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 |
| Support 1 (S1) | 0.11 | 0.12 | 0.11 | 0.11 | 0.11 |
| Support 2 (S2) | 0.11 | 0.11 | 0.11 | 0.11 | |
| Support 3 (S3) | 0.11 | 0.11 | 0.11 | ||
| Support 4 (S4) | 0.11 |
